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Abstract  94 
Background: To expedite international standardized reporting of bone marrow 95 
disease in children with neuroblastoma, to improve equivalence of care.     96 
Methods: A multidisciplinary International Neuroblastoma Response Criteria Bone 97 
Marrow Working Group was convened by the National Cancer Institute in January 98 
2012 with representation from Europe, North America and Australia. Practical 99 
transferable recommendations to standardize reporting of bone marrow disease were 100 
developed.    101 
Results: Consensus criteria for the collection, analysis and reporting of the 102 
percentage area of bone marrow parenchyma occupied by tumor cells in 103 
biopsies/trephines is comprehensively provided for the first time. The quantitative 104 
analysis of neuroblastoma content in bone marrow aspirates by immunocytology (IC) 105 
and reverse transcriptase quantitative polymerase chain reaction (RTqPCR) are 106 
revised. The inclusion of PHOX2b for IHC and RTqPCR is recommended. 107 
Recommendations for recording bone marrow response are provided. We endorse the 108 
quantitative assessment of neuroblastoma cell content in bilateral core 109 
biopsies/trephines and aspirates in all children with neuroblastoma, with the exception 110 
of infants where evaluation of aspirates alone is advised. Notably 5% disease is 111 
accepted as an internationally achievable level for disease assessment.   112 
Conclusion(s): Quantitative assessment of neuroblastoma cells is recommended to 113 
provide data from which evidence-based numerical criteria for the reporting of bone 114 
marrow response can be realised. This is particularly important in the minimal disease 115 
setting and when neuroblastoma detection in bone marrow is intermittent, where 116 
clinical impact has yet to be validated. Wide adoption of these harmonized criteria will 117 
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enhance the ability to compare outcomes from different trials and facilitate 118 
collaborative trial design.   119 
 120 
Introduction  121 
Neuroblastoma is the most common extra-cranial solid tumor in children, and accounts 122 
for 10-15% of all cancer deaths in the first 15 years of life. Metastatic disease at 123 
diagnosis is a powerful predictor of poor outcome and is used in the International 124 
Neuroblastoma Risk Group (INRG) Staging System to select treatment for children at 125 
diagnosis.1,2 Bone marrow is the most common site of infiltration in children presenting 126 
with metastatic disease at diagnosis,2 and a frequent site for relapse and disease 127 
recurrence.3,4 Persistence of neuroblastoma disease in bone marrow is predictive of 128 
poor outcome,5,6,7 and provides a means to assess disease response without having 129 
to wait for the development of greater tumor burden.8,9,10 Thus making it attractive as 130 
part of clinical response criteria.  131 
Cytology of aspirates and histology of biopsies has been the gold standard to assess 132 
neuroblastoma disease in bone marrow for many years.1,2,11 However these methods 133 
have limited sensitivity when neuroblastoma contamination is less than 10%, and 134 
could seriously underestimate the prevalence of bone marrow infiltration.3,12 135 
Significant improvements in the sensitivity and specificity of neuroblastoma cell 136 
detection in bone marrow aspirates have been made such that it is now possible to 137 
unambiguously detect a single neuroblastoma cell in one million normal cells using 138 
immunocytology (IC) or reverse transcriptase quantitative polymerase chain reaction 139 
(RTqPCR).13 Furthermore these quantitative methods have shown that the level of 140 
neuroblastoma cells detected by IC5,14 or RTqPCR15,16,18 in bone marrow is predictive 141 
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of outcome, paving the way for their introduction into clinical practice. Although 142 
consensus criteria for the detection of neuroblastoma cells in bone marrow aspirates 143 
have previously been described,13 there is no comparable published guidance on 144 
evaluation of bone marrow biopsies. So that the definition of bone marrow response 145 
is consistent across international studies, an International Neuroblastoma Response 146 
Criteria Bone Marrow Working Group (INRC BMWG) was convened to define 147 
consensus criteria for the standardized detection and reporting of bone marrow 148 
biopsies, and to review the criteria for analysis of aspirates building on previous 149 
international experience and exploiting new knowledge.  150 
 151 
Methods 152 
The INRC BMWG was assembled, with representation from Europe, North America 153 
and Australia, as a component of the Neuroblastoma Clinical Trials Planning Meeting 154 
held in April 2012 in Washington DC, supported by the National Cancer Institute. 155 
Experts from the INRC BMWG presented new data on neuroblastoma cell detection 156 
using immunohistochemistry (IHC), IC and RTqPCR from the Society International of 157 
Oncology Pediatric-Neuroblastoma (SIOPEN), German Society for Pediatric Oncology 158 
and Hematology (GPOH), &KLOGUHQ¶V2QFRORJ\*URXSCOG) and New Approaches to 159 
Neuroblastoma Therapy (NANT) cooperative groups. Between January 2012 and 160 
September 2014 the INRC BMWG of multidisciplinary experts in pediatric oncology, 161 
pathology, translational biology and statistical methods reviewed the literature, shared, 162 
sought and examined unpublished data and opinion, participating in over 35 163 
teleconference calls. 164 
 165 
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Recommendations for analysis and reporting of neuroblastoma status in bone 166 
marrow  167 
Sample collection, preparation for analysis and storage  168 
Bone marrow samples from at least 2 different sites should be analyzed, usually from 169 
the right and left iliac crest.13,17 We recommend collection of representative bilateral 170 
core biopsies for histology/IHC and bilateral bone marrow aspirates for cytology, IC 171 
and RTqPCR from all children at diagnosis, and for high-risk children at the time of 172 
response assessment at the end of induction therapy; additional time points may be 173 
specified according to trial-specific protocols. We advocate the analysis of biopsies 174 
and aspirates by central reference laboratories where disease infiltration is less than 175 
or equivalent to 5%. In very young or small infants core biopsies are not 176 
recommended, as the size and quality of the biopsy is unlikely to be adequate for 177 
robust analysis. Where feasible, we suggest that the histology/IHC of bone marrow 178 
biopsies and cytology/IC/RTqPCR of bone marrow aspirates are provided in a 179 
combined report so that any concordance or discordance is revealed.  180 
 181 
Bone marrow aspirations from different sites should be performed using separate 182 
syringes, aspirates should not be pooled so that the heterogeneity of neuroblastoma 183 
cell infiltration can be recorded and to avoid underestimating the extent of bone 184 
marrow disease. From the first aspiration (0.1±0.3ml), 5-10 smears of aspirate from 185 
each site should be prepared, air-dried and stained with Pappenheim or modified 186 
Wright stain for initial staging using cytological examination by light microscopy. From 187 
the next 3-5ml of each sample, 0.5ml of each aspirate should be transferred 188 
immediately into RNA preserving tubes such as PAXgeneTM blood RNA tubes for the 189 
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extraction of RNA and RTqPCR. Samples in PAXgeneTM blood RNA tubes can be 190 
stored at -80°C for up to 5 years or at room temperature for up to 3 da ys prior to RNA 191 
extraction.18 The remaining aspirate is transferred into anticoagulant such as 192 
ethylenediaminetetraacetic acid (EDTA) or heparin, and cells isolated using density 193 
gradient centrifugation for the preparation of cytospins for IC; cytospins should be 194 
prepared within 24 hours of aspirate collection (maintained at +4°C to +8 °C) and can 195 
be stored at -20°C until analyzed. 13  196 
 197 
Bone marrow core biopsies should be placed immediately in fixative and decalcified. 198 
We recommend fixation in 4% buffered formalin for 18-24 hours, and decalcification 199 
by incubating in 12.5% EDTA at pH 7.0 for 4-6 hours to preserve morphology and 200 
antigenicity. The fixed, decalcified biopsy should be embedded in paraffin, and a 201 
minimum of five slides mounted with 2-3 sections of 4µm prepared. A minimum of 2 202 
slides should be stained with hematoxylin and eosin (H&E) for histology, the remaining 203 
unstained slides can be used for IHC which is recommended.  204 
 205 
Bone marrow quality 206 
Only bone marrow samples of suitable quality should be investigated for diagnostic 207 
and prognostic purposes. If the sample is inadequate we recommend a repeat 208 
aspiration or biopsy, and reanalysis.  209 
A bone marrow smear is considered representative and suitable for quantitative 210 
reporting of disease when there is greater than 5% tumor cell infiltration. When 211 
infiltration with tumor is less than or equal to 5%, then three of the following four criteria 212 
must be fulfilled to allow discrimination between no disease or minimal disease (i) 213 
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presence of particles with stromal cells e.g. histiocytes, fibroblasts or osteoblasts, (ii) 214 
presence of megakaryocytes, (iii) the erythroblasts exceed 20% of the nucleated cells, 215 
and (iv) peripheral blood cells are within the range for age. i.e. the mature granulocytes 216 
and lymphocytes do not exceed 65% in infants (<1 year of age) or 50% in  children >1 217 
year of age. If these criteria are not met, this should be detailed when reporting on 218 
analysis of the smear.  219 
Cytospins are prepared from mononuclear cells (MNCs) of the bone marrow and do 220 
therefore not contain histiocytes and fibroblasts. Macrophages, granulocytes, 221 
megakaryocytes and erythroblasts may be maintained in the MNC fraction at levels 222 
which are variable and always lower than in a bone marrow smear. Notably, 223 
erythroblasts never exceed 20% of all nucleated cells in a representative cytospin. 224 
Therefore, the above listed quality criteria for bone marrow smears do not apply to 225 
bone marrow cytospins.  226 
The routine aspiration of larger volumes is not recommended to avoid dilution of the 227 
bone marrow with blood, which will reduce the sensitivity of analyses.  Cells with 228 
disrupted cellular or nuclear membranes should not be analyzed.  229 
For RTqPCR each aspirate should yield a minimum of 400ng of RNA, which has an 230 
optical density reading A260/A280 ratio of >1.5 and <3. Amplification of cDNA, generated 231 
from 100ng of RNA, for a house-keeping gene such as ȕ2-microglobulin should 232 
produce a cycle threshold (Ct) <25. Where there is insufficient aspirate to complete all 233 
analyses, the priority for investigations is cytology, followed by RTqPCR and finally IC.    234 
An optimal bone marrow core biopsy should preferably contain red bone marrow 235 
parenchyma at a minimum length of 1cm. This recommendation is derived from 236 
previous published work19 and has since been supported by longstanding experience. 237 
The amount of hematopoietic and tumor tissue within the biopsy should be recorded 238 
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in mm; cortical bone, cartilage, soft tissue, blood clots or areas that are crushed are 239 
excluded from the measurement.   240 
 241 
 242 
Criteria for analysis and reporting of neuroblastoma cell infiltration in bone 243 
marrow core trephine biopsies 244 
x Histology  245 
Metastatic tumor infiltration in bone marrow biopsies is estimated as the surface area 246 
occupied by peripheral neuroblastic tumor (PNT), as a percentage of the evaluable 247 
ERQHPDUURZVSDFHVRQHDFKVLGHRIWKHELRSV\HJ!--<15%, 248 
-%--<30% and so on. Total marrow spaces can include 249 
areas of metastatic neuroblastoma, fibrosis and necrosis, hematopoietic components 250 
and adipose tissue. The Mitosis-Karyorrhexis Index (MKI) should not be attempted as 251 
this is usually not feasible reflecting the limited number of metastatic neuroblastoma 252 
cells in bone marrow biopsy specimens.20 Importantly tumor histology should be 253 
classified as poorly differentiated (PD), undifferentiated (UD) or differentiating.20 In the 254 
case of small tumor aggregates the presence or absence of neuropil (a complex 255 
network of interwoven cytoplasmic processes of nerve cells and neuroglial cells) 256 
detected by IHC for synaptophysin can help to discriminate UD and PD 257 
neuroblastoma. In those rare cases where stroma-rich and stroma-poor histology are 258 
present within a single biopsy, the amount of stroma-rich and stroma-poor tumor 259 
should be recorded as a percentage of the surface area occupied by the tumor (Figure 260 
1).  261 
x Immunohistochemistry (IHC)  262 
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IHC is frequently employed to improve the precision of neuroblastoma detection in 263 
bone marrow biopsies. We encourage IHC of multiple sections (>3 sections) from all 264 
biopsies using a minimum of two antibodies; to minimise cost 3 sections might be 265 
placed on a single slide with each antibody. Highly specific target antigens for which 266 
IHC is unambiguous include synaptophysin, tyrosine hydroxylase, chromogranin A 267 
and paired-like homeobox 2b (PHOX2B). Additional frequently used markers include 268 
CD56 and PGP9.5.11,20,21,22,23,24 Where suspected, Schwann cells can be reliably 269 
detected by morphology and IHC for the S-100 protein.20 Less useful markers for the 270 
detection of neuroblastoma cells in the bone marrow are neuron specific enolase 271 
(NSE) and NB84; NSE because it lacks specificity25 and NB84 because it is rarely 272 
expressed by neuroblastoma cells in the bone marrow.26 The quality of any 273 
immunohistological analysis should be monitored by simultaneous processing of a 274 
positive control sample. Relevant controls can be sections from multi-tissue blocks 275 
including the adrenal gland or other neuroendocrine tissues; an ideal control would 276 
have areas of positive and negative cells.  277 
A bone marrow biopsy is regarded as negative for tumor in the absence of 278 
neuroblastoma cell nests detected by H&E staining and IHC, using a minimum of two 279 
antibodies to analyse at least 3 sections. A case should only be confirmed negative 280 
after assessment of all available sections.  281 
Criteria for analysis and reporting of neuroblastoma cells in bone marrow 282 
aspirates 283 
x Cytomorphology ± bone marrow smears 284 
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Smears should be viewed by light microscopy at low (e.g. 60-100x) and high (e.g. 600-285 
1000x) magnification; at low magnification to assess cellular density and search for 286 
the presence of large tumor cell nests or clumps, and at higher magnification to identify 287 
small tumor cell nests, any potential single neuroblastoma cells and to recognize 288 
features of differentiation. Neuroblastoma nests may contain Homer Wright rosettes, 289 
with neuroblastoma cells in a characteristic ring around a center of neuropil.  290 
 291 
Neuroblastoma cells are typically round and larger than small lymphocytes, with a high 292 
nuclear to cytoplasmic ratio. The cell nucleus can be round or oval, with a fine granular 293 
chroPDWLQVWUXFWXUHVRFDOOHG³VDOWDQGSHSSHU´SDWWHUQ)LJXUH7KLVLVQRWDOZD\V294 
present, therefore it is not obligatory for the description of neuroblastoma. Cells in 295 
nests may range in size from large to intermediate to small, and can be polygonal in 296 
shape, producing a so-FDOOHG ³SDYLQJ VWRQH SDWWHUQ´ $ QHVW RU FOXPS RI W\SLFDO297 
neuroblasts is regarded as the lower threshold for reporting, a nest or clump containing 298 
at least 3 neuroblastoma cells (Figure 2). Granules are not visible, although in 299 
exceptional circumstances emperipolesis, phagocytosis or inclusion bodies may be 300 
detected in neuroblastic cells. Although a rare event, neuroblastoma cells may mature 301 
spontaneously or after therapy (Figure 2); if features of differentiation are detected in 302 
more WKDQRI WXPRUFHOOV WKLVVKRXOGEHUHSRUWHGDV³SUHVHQFHRIGLIIHUHQWLDWLQJ303 
QHXUREODVWRPD FHOOV´ 6LQJOH QHXUREODVWV GHWHFWHG E\ F\WRORJ\ DORQH FDQQRW304 
unequivocally be identified as neuroblastoma cells, and should not be reported as 305 
such (see below).  306 
 307 
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The evaluated cellularity per slide should be reported as this can impact on the 308 
sensitivity of cytology.27 Single cells alone should not be scored as positive, rather we 309 
recommend such samples are reported as suspicious and the presence of 310 
neuroblastoma cells is confirmed or refuted following central review and analysis by 311 
additional methods such as IC. Where no tumor cells are revealed, this should be 312 
recorded as a tumor cell negative bone marrow aspirate.  313 
    314 
x Immunocytology (IC) - cytospins 315 
Ideally, to reach a sensitivity of 1 neuroblastoma cell in 1 x 106 MNCs IC should be 316 
reported on 3 x 106 MNCs per aspirate28 using a monoclonal anti-GD2 317 
disialoganglioside antibody. We endorse the use of clone 14 G2a.13 Bound antibody 318 
can be visualized by light microscopy following enzymatic reaction to produce a stable 319 
chromogen, or immunofluorescence when a fluorescent antibody or reporter is 320 
employed. Criteria for the reliable light microscopic identification of neuroblastoma 321 
cells on immunocytochemically stained slides are published elsewhere and 322 
summarized in Table 1.13 Where immunofluorescence is used we recommend that 323 
digital images of positive cells with image acquisition details are stored, since the 324 
fluorescence will fade with time. Cytospins of control GD2 positive cells must be 325 
processed in parallel to the test samples to manage any inter-assay variation; these 326 
might usefully be bone marrow smears with a moderate to high tumor cell infiltration 327 
or cytospins of a neuroblastoma cell line which contains high and low GD2 expressing 328 
cells such as IMR-32. The number of tumor cells and total number of investigated cells 329 
should be reported, from which the percentage of tumor infiltration can be calculated.  330 
Reverse Transcriptase quantitative Polymerase Chain Reaction (RTqPCR)  331 
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We recommend that RNA extracted from bone marrow aspirates taken at diagnosis is 332 
amplified by RTqPCR for the expression of at least the neuroblastoma mRNAs 333 
tyrosine hydroxylase (TH) and PHOX2B9,16,18. This is most strongly recommended 334 
within the minimal disease setting where neuroblastoma bone marrow contamination 335 
is 5% and heterogeneity of tumor content may have greatest impact.  It is highly 336 
recommended for children with newly diagnosed high-risk disease at the time of entry 337 
into trial and times of response assessment, for example at the end of induction 338 
treatment. 339 
 340 
RNA should ideally be diluted to a minimum concentration of 40ng/µl, and stored in 341 
VLQJOHXVHDOLTXRWVVXFKDVȝOLQD±80°C freezer. We recommend analysis of each 342 
RNA sample in triplicate with each replicate containing 100ng of RNA; the amount of 343 
RNA analyzed should be stated in the report. The results of RTqPCR must be reported 344 
as the cycle threshold (Ct) values so that any discrepancies between biological 345 
repeats can be identified, and using 2-ǻ&W or ±ǻ&W ZKHUH WKH H[SUHVVLRQ RI WKH346 
neuroblastoma mRNAs is normalised to the internal control (in this case ȕ2-347 
PLFURJOREXOLQǻ&W &WRIQHXUREODVWRPa mRNA ± Ct of ȕ2-microglobulin).The lower 348 
Ct for reporting RTqPCR for the neuroblastoma mRNAs is a Ct value of 40. A tumor 349 
QHJDWLYHERQHPDUURZKDVD&W YDOXHRI IRUDOO RI WKHQHXUREODVWRPDP51$V350 
examined, when amplification of the reference house-keeping gene generates a Ct 351 
value of <25. The quality of the amplification curves should be confirmed.28,29,30   352 
 353 
Where possible we strongly recommend reporting results using the comparative Ct 354 
method, also known as the 2-ǻǻ&W method31,32 which reports the fold change in ǻ&W355 
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expression of the sample relative to a calibrator sample that is analyzed in each assay 356 
(ideally on each plate), to control for variation in amplification across different 357 
platforms. We advise that the sensitivity and specificity of RTqPCR analyses across 358 
centres analyzing samples from within clinical trials is maintained by quality control to 359 
minimize inter-laboratory variability.18  360 
 361 
Recommendations for reporting bone marrow response  362 
Currently we recommend >5% bone marrow infiltration as the internationally attainable 363 
level of reliable tumor detection for reporting bone marrow response (Table 2). 364 
Importantly, prospectively the number of neuroblastoma cells and level of 365 
neuroblastoma mRNAs in bilateral bone marrow aspirates and the percentage of 366 
tumor in bilateral bone marrow biopsies should be recorded, to accumulate the data 367 
from which more precise evidence-based response criteria can be defined in the 368 
future. This is essential in the setting of minimal disease (when tumor cell infiltration is 369 
5%), and when infiltration on reassessment is increased two-fold to >5% but does 370 
not reach 20%. Quantitative assessment of bone marrow infiltration is also important 371 
to more precisely evaluate the potential clinical impact of intermittent neuroblastoma 372 
cell detection. Not involved and not evaluable are clearly defined (Tables 1 and 2); 373 
ZKHUHERQHPDUURZVDPSOHVZHUHQRWREWDLQHGWKLVVKRXOGEHUHFRUGHGDVµ1RWGRQH¶374 
(ND or NDPCR for IC and RTqPCR respectively).  In the case of discrepant results 375 
between analysis of multiple bone marrow aspirates and biopsies using any of the 376 
described methods, the sampled site with the highest level of tumor should be utilized 377 
to grade response. Where quantification is not possible locally and for assessment of 378 
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response in early phase 1 and 2 clinical trials, it is recommended that aspirates and 379 
biopsies are collected and analyzed by trial led central review.  380 
 381 
Discussion 382 
For the first time we describe international consensus criteria for the collection, 383 
processing and quantitative reporting of neuroblastoma cells in bone marrow biopsies. 384 
Importantly in biopsies we recommend reporting the percentage area of bone marrow 385 
parenchyma occupied by tumor cells to minimize errors that may arise when the 386 
number of tumor cells in a biopsy is very low, for example after chemotherapy. We 387 
have developed these recommendations with the ambition that they will be suitable 388 
for adoption across all centres treating children with neuroblastoma (Table 4). We 389 
anticipate that, coupled with the updated guidance for assessment of neuroblastoma 390 
cell contamination in bone marrow aspirates, they will facilitate a robust international 391 
standardization of bone marrow reporting. Previous studies have reported on the 392 
variation and inadequacy of bone marrow biopsy quality,19,33 underlining the need for 393 
change, which we anticipate the comprehensive recommendations provided in this 394 
paper will expedite.  395 
 396 
In response to the increased sensitivity and specificity of methods to quantify clinically 397 
relevant neuroblastoma cells in bone marrow, we advocate that children with bone 398 
marrow disease 5% are considered in a separate response category of minimal 399 
disease. Adoption of quantitative reporting of neuroblastoma cell number and mRNA 400 
levels in prospective clinical trials will in the future inform a more precise definition of 401 
what constitutes a response in the setting of minimal disease. This information in the 402 
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long term may inform timely introduction of emerging effective agents to treat bone 403 
marrow disease, with an anticipated improvement in outcome. International adoption 404 
of these recommendations will facilitate cross-trial comparisons and increase 405 
opportunities for collaborative trial design and research, with the expectation that this 406 
will speed the advancement of new treatments to improve outcome for children with 407 
disseminated disease. 408 
 409 
Several studies have reported a greater frequency of neuroblastoma identification in 410 
bone marrow biopsies than in aspirates.34,35 However, there is substantial agreement 411 
that analysis of both should be performed for the most accurate interpretation of bone 412 
marrow disease.35,36,37 This might be particularly important in the minimal disease 413 
setting, when sequential monitoring of bone marrow disease and response evaluation 414 
may be more informative.3,6,7 Therefore we recommend that both bilateral bone 415 
marrow aspirates and biopsies are analyzed, and their clinical value compared 416 
prospectively to inform future practice. The value of IC and IHC are both dependent 417 
on the quality of the sample, and the specificity and sensitivity of the antibodies 418 
employed. For IHC we advise using antibodies against at least two of the 419 
recommended antigens, endorsing the use of synaptophysin and chromogranin A12 420 
and advocating the introduction of PHOX2B.22,23 For IC we support the use of 421 
antibodies to GD2,13 and commend the inclusion of a second antibody (e.g. anti-422 
PHOX2B or anti-CD56) to control for those rare situations where GD2 expression may 423 
be weak or negative.38 39 We advocate the use of RTqPCR within clinical trials to 424 
quantify the level of the neuroblastoma mRNA tyrosine hydroxylase, the most widely 425 
evaluated mRNA target which has prognostic value in bone marrow,13 in all children 426 
in the minimal disease setting and in high-risk children at trial-specific disease 427 
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assessment time-points. In addition we now recommend the adoption of RTqPCR for 428 
PHOX2B mRNA in clinical trials, as this is reported to be a highly specific marker for 429 
the detection of disseminating neuroblastoma cells16 and in combination with tyrosine 430 
hydroxylase may allow the identification of children with drug refractory disease.9 431 
(Figure 3). Additional methods may serve to improve the sensitivity and specificity of 432 
quantitative bone marrow analysis and reporting using IC or RTqPCR, including 433 
automatic immunofluorescence plus FISH (AIPF)39 and assessment of the RNA 434 
integrity number (RIN)40 respectively.   However the dependency of these tests on 435 
specialist equipment prohibits their inclusion as standard recommendations for 436 
assessment of disease. Whilst flow cytometry has been utilized to quantify 437 
neuroblastoma cell content in bone marrow aspirates, a requirement to analyze large 438 
numbers of cells reduces the sensitivity of this approach which is not recommended 439 
in the clinical setting.41 440 
In summary, consensus methods to detect neuroblastoma cells and mRNAs in bone 441 
marrow aspirates and biopsies have been described (Figure 3). The future challenge 442 
will be to empower centres to improve the quality of bone marrow collection from 443 
children with neuroblastoma, and to assess whether these recommendations have 444 
changed practice. Adoption of these consensus recommendations by the international 445 
community will enhance the comparison of results from clinical trials to expedite trial 446 
led change in response assessment, to improve outcome for children with 447 
neuroblastoma.  448 
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Figure 1. Histomorphological features of differentiation. 621 
A. Trephine biopsy after chemotherapy of an initially poorly differentiated 622 
neuroblastoma demonstrating non-neoplastic Schwann cell rich stroma.  623 
B. Contra-lateral trephine biopsy from the same trephine in A. In addition to 624 
sheets of Schwann cells (not shown), only 2 foci of tumor cells are found (areas 625 
marked with dotted lines) which include a sufficient number of differentiating 626 
neuroblasts with abundant cytoplasm (arrows) to fulfill the criteria of a differentiating 627 
neuroblastoma.  628 
C. Trephine biopsy after chemotherapy shows proliferation of non-neoplastic 629 
Schwann cell stroma encasing a few differentiating neuroblasts/ganglion-like cells 630 
either as single cells (long arrows) or in small clusters (short arrows and inset down 631 
left) resembling maturing ganglioneuroma.  632 
 633 
 634 
 635 
 636 
 637 
 638 
 639 
 640 
 641 
 642 
 643 
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Figure 2. Cytomorphological features of differentiation.  644 
A, B.  Neuroblastoma cell nests with poorly differentiated neuroblasts  645 
C.   Neuroblastoma cell clump with varying features of differentiation: increasing 646 
cell size, larger nuclei with bluish nucleoli, more distinct nuclear membrane, coarser 647 
chromatin, polychromatic cytoplasm, neuropil between cells.  648 
D.  Differentiating cells increase even more in size, more compact and coarse 649 
granular chromatin, nuclear membrane like pencil-delineated, few bluish nucleoli, 650 
one bi-nucleated cell  651 
E.  Tumor cell clump with 5 differentiating cells: large nuclei with big nucleoli, 652 
extensive polychromatic cytoplasm   653 
F.  Tumor cell nest with undifferentiated cells and one differentiated giant 654 
ganglionic-like cell with abundant cytoplasm and two nuclei and extra chromatin. 655 
Both nuclei contain 3-4 bluish nucleoli.  656 
 657 
  658 
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Figure 3. Consensus recommendations for analysis of bone marrow biopsies 659 
and aspirates 660 
Analysis of both bilateral bone marrow biopsies and aspirates is recommended. We 661 
advise IHC of multiple sections using antibodies against at least two of the 662 
recommended antigens and advocate the inclusion of PHOX2B. For IC we support 663 
the analysis of at least 3 x 106 MNCs per aspirate using a monoclonal anti-GD2 664 
disialoganglioside antibody; a second antibody may be included to control for those 665 
rare situations where GD2 expression is weak or negative. Within clinical trials we 666 
recommend RTqPCR of RNA extracted from bone marrow aspirates to quantify the 667 
level of the neuroblastoma mRNAs tyrosine hydroxylase and PHOX2B. The results 668 
of RTqPCR must be reported as the Ct value and using 2-ǻ&W or ±ǻ&W, where the 669 
expression of the neuroblastoma mRNAs is normalised to an internal control; we 670 
recommend ȕ2-microglobulin. 671 
